Haleon, Futura Medical’s commercial partner for Eroxon in the US market, has announced it intends to make Eroxon available in the US before the end of 2024. Haleon had previously only stated, during analyst Q&A as part of FY23 results in February, that US launch was expected “within the next 12 months” ie by February 2025. The importance of the clarification lies in the timing of the expected US launch milestone being triggered, which should propel Futura to profitability in FY24. Our current forecasts conservatively model a US launch in FY25.